Tempus AI Shares Rise Friday on Merck-Moderna Trial Results

Tempus AI Inc. shares moved higher on Friday, as traders continued to digest the aftermath of this week's Merck-Moderna clinical trial headlines.

Tempus AI stock is receiving positive attention. What is driving TEM shares higher?

What sparked Tempus AI's recent price action?

TEM's recent catalyst comes from Merck & Co. and Moderna Inc.'s Phase 3 INTerpath-001 trial results, where intismeran autogene combined with Keytruda improved recurrence-free survival in patients with resected melanoma, described as the first successful Phase 3 readout for a customized mRNA cancer treatment.

This personalized vaccine relies on Personalis Inc.'s genomic tumor profiling technology, which Moderna uses to analyze patient tissue and identify specific neoantigens to create customized doses.

This connection directly benefits Tempus AI, which agreed last month to acquire Personalis for $1.5 billion, having previously collaborated with the company on minimal residual disease testing. The acquisition provides Tempus with key sequencing infrastructure supporting Moderna's therapeutic program, just as that program reaches a major Phase 3 clinical milestone.

Tempus CEO Eric Lefkofsky highlighted this connection on social media Wednesday, congratulating Moderna and Merck while noting Tempus's pride in supporting the breakthrough program.

Congratulations to @moderna_tx and @Merck on today's positive Phase 3 INTerpath-001 results, a major milestone for melanoma treatment and the future of more personalized medicine.

We are proud to partner with Moderna in supporting this important program, and we look forward to seeing...

— Eric Lefkofsky August 19, 2026

Key levels to watch for TEM stock

TEM is elevated relative to its trend indicators, trading about 33% above its 20-day simple moving average and roughly 19.7% above its 200-day simple moving average, which typically increases the likelihood of a pause or pullback even if the larger move remains intact. This rise comes against a longer-term backdrop still burdened by a January death cross, a reminder that the stock can remain volatile when momentum cools.

The relative strength index is currently the clearer momentum gauge: at 71.53, it sits in overbought territory, which typically signals the move has become "overextended" and may mean upside becomes harder to sustain without a reset. The key question for trend traders is whether any decline is shallow or begins to close the gap with major moving averages.

Key resistance: $76.50 — a nearby pivot zone where a bounce could stall after the rapid rise

Key support: $61.50 — the recent bottom area, relatively close to the current price, which can define whether a pullback remains controlled

TEM stock's price action on Friday

TEM price action: As of Friday's data release, Tempus AI shares were up 5.09% at $70.04.